ABBV logo AbbVie +
AbbVie
+

AbbVie (ABBV) Business News

Track AbbVie in real time with a live news feed covering AbbVie stock news, official press releases, company announcements, and an archive of historical AbbVie news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval

GuruFocus

11:19 AM | Tuesday | Sep 29, 2026

news photo
Loading...

AbbVie (ABBV), the immunology and neuroscience drugmaker, secured FDA approval for Juvmo, a once-daily Parkinson's treatment. Its shares dropped nearly 0.8% to

Read full article redirect
11:19 AM | Tuesday | Sep 29, 2026

AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval

GuruFocus

AbbVie (ABBV), the immunology and neuroscience drugmaker, secured FDA approval for Juvmo, a once-daily Parkinson's treatment. Its shares dropped nearly 0.8% to

Read full article arrow
News Thumbnail
10:41 AM | Tuesday | Sep 29, 2026

UnitedHealth, AbbVie And A Health Care Stock On CNBC's ‘Final Trades'

Benzinga

On CNBC's “Halftime Report Final Trades,” Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, picked UnitedHealth Group Incorporated (NYSE:UNH).

Read full article arrow
News Thumbnail
9:00 AM | Tuesday | Sep 29, 2026

AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development

PRNewsWire

AbbVie deepens investment in artificial intelligence (AI) by entering into a new collaboration with Valkai to strengthen integrated AI capabilities across clinical development AbbVie is committed to integrating AI throughout the drug development journey to advance scientific innovation, strengthen operations and improve outcomes for patients NORTH CHICAGO, Ill., Sept. 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation reaches patients.

Read full article arrow
News Thumbnail
8:00 AM | Tuesday | Sep 29, 2026

Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

Business Wire

BOSTON--(BUSINESS WIRE)--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium.

Read full article arrow
News Thumbnail
8:00 AM | Monday | Sep 28, 2026

U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease

PRNewsWire

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients a differentiated approach to motor symptom control across the Parkinson's disease continuum Approval is supported by the Phase 3 TEMPO program demonstrating significant improvements in daily functioning, increased "on" time without troublesome dyskinesia and a favorable safety profile NORTH CHICAGO, Ill., Sept. 28, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease, a progressive neurological disorder that affects millions of people worldwide.

Read full article arrow
News Thumbnail
7:45 AM | Saturday | Sep 26, 2026

Best Dividend Kings: September 2026

Seeking Alpha

Dividend Kings are underperforming SPY in September, with a -4.22% average return versus SPY's marginal gain. Despite aggregate weakness, 29 Dividend Kings appear both undervalued and offer a long-term expected return of at least 10%. Recent dividend increases and higher projected earnings growth have modestly improved the Kings' average dividend growth rate to 4.49%.

Read full article arrow
News Thumbnail
11:01 AM | Friday | Sep 25, 2026

ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade

24/7 Wall Street

AbbVie and Johnson and Johnson both trade near 52-week highs and carry decades of dividend raises, but one faces a patent cliff and a leveraged balance sheet that could force retirees to rethink their income strategy completely.

Read full article arrow
News Thumbnail
4:21 AM | Friday | Sep 25, 2026

AbbVie (NYSE:ABBV) Reaches New 12-Month High – What’s Next?

Defense World

AbbVie Inc. (NYSE: ABBV - Get Free Report) hit a new 52-week high during mid-day trading on Wednesday. The company traded as high as $268.41 and last traded at $266.4530, with a volume of 189319 shares traded.
The stock had previously closed at $265.21. Trending Headlines about AbbVie Here are the key news stories impacting AbbVie

Read full article arrow
News Thumbnail
12:45 PM | Thursday | Sep 24, 2026

Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?

Zacks Investment Research

AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.

Read full article arrow
News Thumbnail
12:06 PM | Thursday | Sep 24, 2026

Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio?

Zacks Investment Research

ABBV is expanding its oncology pipeline with newer therapies and diverse approaches to offset Imbruvica's decline.

Read full article arrow
News Thumbnail